Currently Enrolling:
A phase II study of binimetinib in combination with imatinib in patients with advanced KIT-mutant melanoma
NCT04598009
PIs: Katy Tsai, MD; Iwei Yeh, MD, PhD
Sponsor: Pfizer
Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) Combination in Metastatic Melanoma Refractory to Prior Immune Checkpoint Inhibitor Therapy with and without CNS Disease
NCT05695898
PIs: Adil Daud, MD; Saya Jacob, MD
Sponsor: Xencor